More importantly, we also identified highly significant differences in serum cytokine profile between the two outcome cohorts of long‐term and minimal survival benefit at the timepoints after 2 and 4 cycles' treatment, but not the baseline before treatment.
← all excerpts
The efficacy and safety of the combination of axitinib and pembrolizumab-activated autologous DC-CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study.
1
—
—